BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25726258)

  • 1. A Common Source Outbreak of Severe Delirium Associated with Exposure to the Novel Synthetic Cannabinoid ADB-PINACA.
    Schwartz MD; Trecki J; Edison LA; Steck AR; Arnold JK; Gerona RR
    J Emerg Med; 2015 May; 48(5):573-80. PubMed ID: 25726258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: A case series and review of the literature.
    Armenian P; Darracq M; Gevorkyan J; Clark S; Kaye B; Brandehoff NP
    Neuropharmacology; 2018 May; 134(Pt A):82-91. PubMed ID: 29037744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA.
    Banister SD; Moir M; Stuart J; Kevin RC; Wood KE; Longworth M; Wilkinson SM; Beinat C; Buchanan AS; Glass M; Connor M; McGregor IS; Kassiou M
    ACS Chem Neurosci; 2015 Sep; 6(9):1546-59. PubMed ID: 26134475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA.
    Tyndall JA; Gerona R; De Portu G; Trecki J; Elie MC; Lucas J; Slish J; Rand K; Bazydlo L; Holder M; Ryan MF; Myers P; Iovine N; Plourde M; Weeks E; Hanley JR; Endres G; St Germaine D; Dobrowolski PJ; Schwartz M
    Clin Toxicol (Phila); 2015; 53(10):950-6. PubMed ID: 26555732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The metabolism of the synthetic cannabinoids ADB-BUTINACA and ADB-4en-PINACA and their detection in forensic toxicology casework and infused papers seized in prisons.
    Kronstrand R; Norman C; Vikingsson S; Biemans A; Valencia Crespo B; Edwards D; Fletcher D; Gilbert N; Persson M; Reid R; Semenova O; Al Teneiji F; Wu X; Dahlén J; NicDaéid N; Tarbah F; Sutcliffe OB; McKenzie C; Gréen H
    Drug Test Anal; 2022 Apr; 14(4):634-652. PubMed ID: 34811926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schedules of Controlled Substances: Extension of Temporary Placement of PB-22, 5F-PB-22, AB-FUBINACA and ADB-PINACA in Schedule I of the Controlled Substances Act. Final order.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2016 Feb; 81(24):6175-7. PubMed ID: 26859904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schedules of Controlled Substances: Temporary Placement of Six Synthetic Cannabinoids (5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA) into Schedule I. Temporary Scheduling Order.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2017 Apr; 82(67):17119-24. PubMed ID: 28425681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Convulsant doses of abused synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA and JWH-018 do not elicit electroencephalographic (EEG) seizures in male mice.
    Wilson CD; Zheng F; Fantegrossi WE
    Psychopharmacology (Berl); 2022 Oct; 239(10):3237-3248. PubMed ID: 35933518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coma, Seizures, Atrioventricular Block, and Hypoglycemia in an ADB-FUBINACA Body-Packer.
    Nacca N; Schult R; Loflin R; Weltler A; Gorodetsky R; Kacinko S; Moran J; Krotulski A; Wiegand T
    J Emerg Med; 2018 Dec; 55(6):788-791. PubMed ID: 30297193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabimimetic effects of abused indazole-carboxamide synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA and 5F-ADB-PINACA in mice: Tolerance, dependence and withdrawal.
    Wilson CD; Hiranita T; Fantegrossi WE
    Drug Alcohol Depend; 2022 Jul; 236():109468. PubMed ID: 35643039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schedules of Controlled Substances: Temporary Placement of Six Synthetic Cannabinoids (5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB- CHMICA and MDMB-FUBINACA) Into Schedule I. Notice of Intent.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2016 Dec; 81(245):93595-9. PubMed ID: 28068047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA.
    Kevin RC; Wood KE; Stuart J; Mitchell AJ; Moir M; Banister SD; Kassiou M; McGregor IS
    J Psychopharmacol; 2017 Jun; 31(6):757-769. PubMed ID: 28093016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential cannabinoid-like effects and pharmacokinetics of ADB-BICA, ADB-BINACA, ADB-4en-PINACA and MDMB-4en-PINACA in mice: A comparative study.
    Zhou F; Wang X; Tan S; Shi Y; Xie B; Xiang P; Cong B; Ma C; Wen D
    Addict Biol; 2024 Feb; 29(2):e13372. PubMed ID: 38380735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supraventricular tachycardia and acute confusion following ingestion of e-cigarette fluid containing AB-FUBINACA and ADB-FUBINACA: a case report with quantitative analysis of serum drug concentrations.
    Lam RPK; Tang MHY; Leung SC; Chong YK; Tsui MSH; Mak TWL
    Clin Toxicol (Phila); 2017 Aug; 55(7):662-667. PubMed ID: 28393558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinguishing Intake of New Synthetic Cannabinoids ADB-PINACA and 5F-ADB-PINACA with Human Hepatocyte Metabolites and High-Resolution Mass Spectrometry.
    Carlier J; Diao X; Scheidweiler KB; Huestis MA
    Clin Chem; 2017 May; 63(5):1008-1021. PubMed ID: 28302730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatal intoxication of a regular drug user following N-ethyl-hexedrone and ADB-FUBINACA consumption.
    Kovács K; Kereszty É; Berkecz R; Tiszlavicz L; Sija É; Körmöczi T; Jenei N; Révész-Schmehl H; Institóris L
    J Forensic Leg Med; 2019 Jul; 65():92-100. PubMed ID: 31128567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UPLC/ESI-MS/MS-based determination of metabolism of several new illicit drugs, ADB-FUBINACA, AB-FUBINACA, AB-PINACA, QUPIC, 5F-QUPIC and α-PVT, by human liver microsome.
    Takayama T; Suzuki M; Todoroki K; Inoue K; Min JZ; Kikura-Hanajiri R; Goda Y; Toyo'oka T
    Biomed Chromatogr; 2014 Jun; 28(6):831-8. PubMed ID: 24861751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe illness associated with reported use of synthetic cannabinoids: a public health investigation (Mississippi, 2015).
    Kasper AM; Ridpath AD; Gerona RR; Cox R; Galli R; Kyle PB; Parker C; Arnold JK; Chatham-Stephens K; Morrison MA; Olayinka O; Preacely N; Kieszak SM; Martin C; Schier JG; Wolkin A; Byers P; Dobbs T
    Clin Toxicol (Phila); 2019 Jan; 57(1):10-18. PubMed ID: 29989463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and Pharmacological Profiling of the Metabolites of Synthetic Cannabinoid Drugs APICA, STS-135, ADB-PINACA, and 5F-ADB-PINACA.
    Longworth M; Connor M; Banister SD; Kassiou M
    ACS Chem Neurosci; 2017 Aug; 8(8):1673-1680. PubMed ID: 28574245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schedules of Controlled Substances: Placement of PB-22, 5F-PB-22, AB-FUBINACA and ADB-PINACA into Schedule I. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2016 Sep; 81(172):61130-3. PubMed ID: 27632803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.